Abstract:B271 Introduction: The tumor suppressor p53 is a key regulator of cell cycle, apoptosis, senescence and DNA repair. Due to its important role in oncogenesis, it is not surprising that p53 function is compromised in all human cancers. In half the cancers, p53 gene is directly mutated/deleted, rendering p53 protein inactive, while in the remaining cancers with wild-type p53, p53 function is effectively inhibited by its cellular endogenous inhibitor the minute double minute 2 (MDM2) protein through direct interaction. Thus, targeting the MDM2-p53 interaction by small-molecule inhibitors is a promising approach for the reactivation of p53 function, and is being intensely pursued as a cancer therapeutic strategy. Since MDM2 is an essential regulator of p53 activity, there is a serious concern that unleashing p53 function by small-molecule inhibitors of MDM2 may result in toxicity to normal healthy tissues, casting doubts on the suitability of MDM2 inhibitors as potential cancer therapeutic strategy. Methods: We employed multiple human cancer cell line and xenograft tumor models, including SJSA-1 osteosarcoma and LNCaP prostate cancer, and performed following assays/procedures: 1) Binding affinity was determined in fluorescence polarization-based binding assays, 2) cell growth by WST assay, 3) cell cycle by BrdU incorporation, 4) apoptosis by Annexin V staining, 5) MDM2-p53 interaction by co-immunoprecipitation, 6) p53 was downregulated by siRNA oligonucleotide, 7) oral availability by pharmacokinetic (PK) studies, 8) p53 activation by immunohistochemistry and immunoblotting, 9) cell proliferation in tissues by BrdU incorporation, 10) apoptosis in tissues by TUNEL staining, 11) anti-tumor activity in xenograft models, 12) toxicity by animal body weight and necropsy, and 13) normal tissue damage by histopathology. Results: Employing a computational structure-based approach, we have designed a new, highly potent (K i = 5 nM) and selective (>10,000-fold over MDM2 homologue MDMX), orally-available small-molecule MDM2 inhibitor (MI-219) with a distinctively different chemical structure from other known MDM2 inhibitors. MI-219 disrupts intracellular MDM2-p53 interaction in cancer cell lines, leading to accumulation and activation of p53. p53 pathway is activated in both normal and cancer cells with wild-type p53, and leads to cell cycle arrest in both normal and cancer cells with wild-type p53, but selective apoptosis in cancer cells. Induction of cell cycle arrest and apoptosis is strictly p53-dependent. MI-219 has excellent oral bioavailability in mice and rats. A single oral dose of MI-219 induces rapid, but transient, activation of p53 in xenograft tumors and normal mouse tissues, strongly correlating with the plasma levels of MI-219. Multiple oral dosing of MI-219 potently inhibits tumor growth without causing animal weight loss or other signs of toxicity. Importantly, therapeutically effective dose schedules of MI-219 do not result in any damage to normal radio-sensitive and radio-resistant tissues. Conclusion: We conclude that activation of p53 by potent and specific small-molecule MDM2 inhibitors is selectively toxic to tumors without causing damage to normal tissues. Our study thus provides a strong rationale to advance MI-219 or its analogues for clinical development as a new and promising cancer therapeutic strategy.

A structure-based virtual screening identifies a novel MDM2 antagonist in the activation of the p53 signaling and inhibition of tumor growth

Small Molecule Inhibitors of the P53-Mdm2

Pharmacological Activation of the P53 Pathway by a New Compound CYZ2017 Exerts Anti-Tumor Effects

Molecular Modeling and Molecular Dynamics Simulation Studies on Pyrrolopyrimidine-Based Α-Helix Mimetic As Dual Inhibitors of MDM2 and MDMX

Rapid identification of dual p53-MDM2/MDMX interaction inhibitors through virtual screening and hit-based substructure search

The Discovery of Potential MDM2 Inhibitors: A Combination of Pharmacophore Modeling, Virtual Screening, Molecular Docking Studies, and in vitro/in vivo Biological Evaluation

Integrated virtual screening and molecular dynamics simulation revealed promising drug candidates of p53-MDM2 interaction

Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53

A Novel Orally Active Mdm2 Inhibitor (Mi-219) Activates the P53 Pathway and is Selectively Toxic to Tumor Cells

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

Identification of Novel Inhibitors of P53–mdm2 Interaction Facilitated by Pharmacophore-Based Virtual Screening Combining Molecular Docking Strategy

Structure-Based Discovery of MDM2/4 Dual Inhibitors that Exert Antitumor Activities against MDM4-Overexpressing Cancer Cells

190 Novel Classes of P53 Activators for Cancer Therapy

Structural effects and competition mechanisms targeting the interactions between p53 and MDM2 for cancer therapy

Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials

Discovery, Synthesis, and Biological Evaluation of Orally Active Pyrrolidone Derivatives As Novel Inhibitors of P53-Mdm2 Protein-Protein Interaction.

Temporal Activation of P53 by A Specific Mdm2 Inhibitor is Selectively Toxic to Tumors and Leads to Complete Tumor Growth Inhibition

The initial evaluation of non-peptidic small-molecule HDM2 inhibitors based on p53-HDM2 complex structure.

Synthesis and biological evaluation of 4-imidazolidinone–containing compounds as potent inhibitors of the MDM2/p53 interaction

Small Molecules Simultaneously Inhibiting P53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (hdacs): Discovery of Novel Multitargeting Antitumor Agents

D-Peptide Inhibitors of the P53-Mdm2 Interaction for Targeted Molecular Therapy of Malignant Neoplasms